XML 51 R34.htm IDEA: XBRL DOCUMENT v3.23.3
License and Collaboration Agreements (Details)
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 05, 2022
USD ($)
Dec. 14, 2020
USD ($)
Oct. 06, 2020
USD ($)
Nov. 01, 2019
USD ($)
Oct. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Jan. 31, 2022
USD ($)
Oct. 31, 2021
USD ($)
Feb. 28, 2021
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2023
EUR (€)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Research and development                   $ 45,977,000 $ 63,641,000 $ 188,253,000 $ 180,968,000      
Equity method investment                   5,365,000   5,365,000   $ 12,817,000    
Collaboration revenue - related party                   43,000 49,000 139,000 196,000      
Payments for investments                       $ 369,927,000 200,318,000      
Pfizer                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Royalty obligation period from date of first sale                       12 years        
University Of Texas MD Anderson Cancer Center                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration agreement, upfront payment                             $ 3,000,000  
Collaboration agreement term     5 years                          
Committed funding     $ 15,000,000                          
University Of Texas MD Anderson Cancer Center | Subsequent Event                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration agreement, upfront payment         $ 3,000,000                      
Allogene Overland, Allogene Overland BioPharm (HK) Limited                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration revenue - related party                   100,000 100,000 $ 100,000 200,000      
Reduction to research and development expense                   0 300,000 100,000 600,000      
Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Equity method investment, impairment                           0    
Antion                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Research and development           $ 1,000,000                    
Warrants and rights outstanding           3,000,000                    
Investment in equity securities           1,000,000       4,000,000   4,000,000   3,000,000    
Research and development | University Of Texas MD Anderson Cancer Center                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration arrangement, expense                   200,000 200,000 $ 1,200,000 1,100,000      
Research and development | Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaborative agreement, company's right to terminate, period to provide written notice                       90 days        
Collaboration arrangement, expense                   0 1,000,000 $ 1,800,000 2,800,000      
Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Equity method investment       $ 5,000,000                        
Ownership percentage       25.00%                        
Payments for additional investment in interest               $ 1,800,000 $ 15,900,000              
Equity method investment, impairment                   3,000,000   3,000,000   0    
Notch Therapeutics, Inc. | Voting Interest                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Ownership percentage               23.00% 20.70%              
Allogene Overland                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Equity method investment                   0   0   0    
Ownership percentage   49.00%                            
Allogene Overland | Overland Pharmaceuticals Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Ownership percentage   51.00%                            
Research Collaboration and License Agreement | Cellectis                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Maximum payments required per product against selected target                       185,000,000        
Research Collaboration and License Agreement | Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payable                   7,250,000   7,250,000        
License and Collaboration Agreement | Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration agreement, upfront payment       $ 10,000,000                        
Corporate Joint Venture | Allogene Overland | Overland Pharmaceuticals Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Upfront and quarterly cash payments   $ 117,000,000                            
Joint venture capital support payments   40,000,000                            
Corporate Joint Venture | Allogene Overland | Allogene Overland, Allogene Overland BioPharm (HK) Limited                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments   40,000,000                            
Collaboration agreement, upfront payment   $ 40,000,000                            
Antion Collaboration Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration agreement, upfront payment $ 3,500,000                              
Collaboration arrangement, expense                   0 600,000 1,800,000 4,500,000      
Prior investment obligation           3,000,000                    
Costs incurred related to milestone achievement                   400,000 0 400,000 0      
Antion Collaboration Agreement | Current Accrued and Other Liabilities                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaboration arrangement, expense                       400,000   500,000    
Antion Collaboration Agreement | Preferred Stock                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Payments for investments             $ 3,000,000                  
Preferred stock investment payable           $ 2,000,000                    
Antion Collaboration Agreement, Milestone Achievement One                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payable 35,300,000                              
Antion Collaboration Agreement, Milestone Achievement Two                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payable $ 2,000,000                              
Asset Contribution Agreement | Pfizer                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       325,000,000        
Milestone payments                   0 0 0 0      
Asset Contribution Agreement | Minimum | Pfizer                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       30,000,000        
Asset Contribution Agreement | Maximum | Pfizer                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       60,000,000        
Aggregate potential regulatory and development milestones                       840,000,000        
Pre-Clinical Development Milestone | Research Collaboration and License Agreement | Cellectis                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Research and development                   0 0 0 0      
Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement | Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       4,000,000        
Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement | Notch Therapeutics, Inc.                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       283,000,000        
Development and Sales | Maximum | Research Collaboration and License Agreement | Cellectis                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       $ 2,800,000,000        
Related Party | Allogene Overland, Allogene Overland BioPharm (HK) Limited                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Net cost recoveries                   0 300,000   600,000      
Related Party | License and Collaboration Agreement | Servier                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Percentage of development costs payable by the Company                       60.00%        
Percentage of development cost payable by collaboration partner                       40.00%        
Net cost recoveries                   100,000 $ 3,800,000 $ 400,000 $ 20,400,000      
Due from related parties                   0   0   $ 1,500,000    
Related Party | Regulatory Milestone | License and Collaboration Agreement | Servier                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone receivable                   42,000,000   42,000,000        
Related Party | Regulatory Milestone | Maximum | License and Collaboration Agreement | Servier                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       137,500,000        
Related Party | Sales Milestone | License and Collaboration Agreement | Servier                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone receivable                   $ 74,500,000   74,500,000       € 70.5
Related Party | Sales Milestone | Maximum | License and Collaboration Agreement | Servier                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Aggregate potential milestone payments                       $ 78,000,000        
Cellectis | Research Collaboration and License Agreement                                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                
Collaborative agreement, breech of obligation, period to cure                       90 days        
Collaborative agreement, company's right to terminate, period to provide written notice                       60 days        
Collaborative agreement, option to terminate, period after material breech                       90 days        
Collaborative agreement, option to terminate, period after change in control                       60 days